Orphan drugs threatened with illegal hurdle, warns German pharma association
This article was originally published in Scrip
Executive Summary
The BPI, an association representing mainly innovative German pharma firms, is concerned that the G-BA, the joint federal healthcare committee, will require some orphan drugs to undergo the new rapid benefit assessment that is replacing free pricing for new drugs. Germany's controversial new healthcare law (the Amnog) had seemingly exempted most orphan drugs from the assessment, and Dr Alexander Natz, head of the BPI's Brussels office, told Scrip that a legal battle could ensue as BPI believed that the actions G-BA was proposing would be illegal.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.